Core Viewpoint - The structural reform of the OTC market in the U.S. set to launch in July 2025, particularly the new OTCID segment, offers a low-barrier compliance and high-certainty growth opportunity for small and medium-sized enterprises (SMEs) seeking to enter the U.S. capital market [1] Group 1: OTCID Segment Overview - The OTCID segment is particularly suitable for Chinese enterprises, with 777 Chinese companies already listed on the U.S. OTC market, most starting from OTCID [1] - Companies can go public within three months through a shell acquisition without needing to establish complex red-chip structures, with financing scales increasing from millions to tens of millions of dollars [1] - Hard tech companies, such as those in renewable energy and quantum computing, can connect with U.S. investors during non-profitable stages to meet funding needs for R&D expansion [1] Group 2: Target Audience and Compliance - OTCID focuses on three core audiences: early-stage startups needing to showcase potential, micro-cap companies requiring liquidity support, and Chinese companies needing to adapt to U.S. regulatory environments [2] - Unlike OTCQX, OTCID has minimal hard financial metrics, requiring only unaudited financial reports submitted via the OTCIQ platform, with deadlines of 45 days for quarterly and 90 days for annual disclosures [2] - This "light compliance" design allows tech companies in R&D and manufacturing firms in accumulation phases to enter the public market without incurring high auditing and governance costs [2] Group 3: Advancement Path and Market Recognition - OTCID provides a clear advancement path for companies, allowing them to build credibility through continuous disclosures and seamlessly upgrade to OTCQB or OTCQX, eventually aiming for a NASDAQ listing [2] - The case of AI company ADX illustrates this pathway, having upgraded from the pink sheets to OTCID and planning to transition to NASDAQ by 2026, with five OTC companies successfully transitioning in September 2025, averaging over threefold market value growth post-transition [2][3] Group 4: Compliance and Strategy Recommendations - While OTCID has low barriers, it does not equate to a lack of regulation; companies must hire certified transfer agents to maintain shareholder records and disclose significant events within four business days [3] - Companies are advised to adopt a "three-step" strategy for OTCID: establish compliance foundations, engage in story marketing by regularly updating operational progress, and create ecological linkages with market makers to enhance liquidity [4][5] - A warning is issued that compliance is an ongoing responsibility, as evidenced by seven companies being downgraded to the pink sheets for failing to update company information for six consecutive months [5]

Group 1 - The core viewpoint of the article discusses the process and considerations for domestic companies applying directly for OTC listing in the U.S., highlighting the case of HNIT, which plans to list on OTCQB by March 2025 to finance its global health industry expansion [2] - The costs associated with the OTC application include U.S. legal fees, PCAOB audit fees, financial accounting fees during the audit period, EDGAR printer fees, and OTC Market application fees [3] - The article outlines that the total estimated cost for the OTC listing process is approximately $400,000 [5] Group 2 - Companies must prepare existing financial statements (balance sheet, income statement, cash flow statement) for at least six months, and can still list even if they are currently operating at a loss, as future growth potential is the main focus [5] - The listing process involves several steps, including financial accounting, audit report issuance, drafting and submitting the prospectus, responding to SEC inquiries, Form 211 submission, OTC approval, and finally, listing [5] - The expected timeline for the listing process is 9 to 12 months, with 1 to 5 months for pre-submission, 6 to 9 months for F-1 effectiveness, and subsequent listing [5]